4baseCare Raises $13.3M Series B to Expand AI-Powered Cancer Diagnostics Globally

Hitesh Goswami and Kshitij Rishi, 4baseCare Founders

Bengaluru-based precision oncology startup 4baseCare has secured a total of Rs 128 crore ($13.3 million) in funding, reinforcing investor confidence in AI-driven cancer diagnostics and personalized treatment solutions.

The latest top-up round of Rs 38 crore was led by growX Ventures and Infosys, with participation from existing investors. The funding follows the first close of the company's Series B round, which raised Rs 90 crore earlier in 2026 from investors including Ashish Kacholia, Lashit Sanghvi, and Yali Capital.

The fresh capital will support the expansion of 4baseCare's genomics laboratory infrastructure and accelerate the development of its AI-led oncology platform, targeting underserved cancer patients across emerging markets.

What Problem Is 4baseCare Solving in Cancer Care?

Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare focuses on making precision oncology more accessible and affordable in emerging markets.

Cancer treatment traditionally relies on generalized treatment protocols. However, advances in genomics have enabled more personalized approaches, where therapies are tailored based on a patient's genetic profile.

4baseCare's flagship platform, OncoTwin, combines clinico-genomic data with real-world patient insights to help oncologists identify optimal treatment pathways. The platform leverages artificial intelligence to improve clinical decision-making and support personalized cancer care.

The company is specifically targeting populations that have historically been underrepresented in global genomic databases, including patients across India, the Middle East, Southeast Asia, Latin America, and other emerging regions.

How Large Is 4baseCare's Current Footprint?

Since its launch, 4baseCare has established a growing network of genomics laboratories across multiple markets.

Metric	Current Status
Founded	2019
Headquarters	Bengaluru, India
Total Funding Raised	Rs 128 crore ($13.3 million)
Genomic Tests Conducted Monthly	~1,500
Target Monthly Testing Volume	8,000–10,000
Existing Laboratory Markets	India, Dubai, Nepal, Philippines
Planned Expansion	8–10 new countries within 12–18 months

The company currently operates laboratories in four countries and intends to enter 8–10 additional markets over the next 12–18 months.

Why Is 4baseCare Expanding Through Hospital Partnerships?

Beyond standalone laboratories, 4baseCare is building an in-hospital genomics infrastructure model designed to integrate precision diagnostics directly into healthcare systems.

The startup has already partnered with major healthcare institutions, including:

• AIIMS Jammu
• Max Healthcare
• Shankara Hospital

This approach enables faster adoption of genomic testing while improving physician access to personalized oncology insights at the point of care.

Why Are Investors Increasingly Backing Oncology Startups?

Investor interest in oncology-focused startups has strengthened as precision medicine, AI diagnostics, and genomic technologies gain wider clinical adoption.

Several notable funding rounds over the past year include:

Startup	Funding Raised
Everhope Oncology	$10 million Seed Round
MOC Cancer Care & Research Centre	$18 million
ErlySign	Undisclosed
OnCare	Undisclosed
OneCell Diagnostics	Undisclosed

The broader trend reflects growing demand for personalized cancer treatment solutions, particularly across emerging healthcare markets where genomic testing penetration remains relatively low.

As governments and healthcare providers increasingly prioritize precision medicine, startups such as 4baseCare are positioning themselves at the intersection of biotechnology, artificial intelligence, and healthcare infrastructure.

What Does 4baseCare's Growth Signal for Emerging Market Healthcare?

4baseCare's expansion strategy highlights a broader shift toward localized precision oncology ecosystems in emerging markets. By combining AI-powered clinical decision support with genomics infrastructure, the company is addressing critical gaps in cancer diagnosis and treatment accessibility.

With plans to expand into up to 10 new countries and increase testing volumes by more than 500%, 4baseCare is positioning itself as one of the key players shaping the future of precision oncology across Asia, the Middle East, and other underserved healthcare markets.

 

 

FAQ

1. What is 4baseCare and what does it do?
4baseCare is a Bengaluru-based precision oncology startup that develops genomics-based cancer diagnostics and AI-powered clinical decision support solutions for personalized cancer treatment.

2. How much funding has 4baseCare raised to date?
The company has raised a total of Rs 128 crore ($13.3 million), including a recent Rs 38 crore top-up round led by growX Ventures and Infosys.

3. What is OncoTwin?
OncoTwin is 4baseCare's flagship AI-driven oncology platform that uses clinico-genomic and real-world patient data to generate treatment insights for oncologists.

4. Which markets is 4baseCare targeting for expansion?
The company is expanding across India, the Middle East, Southeast Asia, Latin America, and other emerging markets, with plans to enter 8–10 new countries.

5. Why are investors interested in precision oncology startups?
Investors are increasingly backing precision oncology companies due to growing demand for personalized cancer treatment, genomic diagnostics, AI-enabled healthcare, and improved patient outcomes.